

Edgar Filing: MEDICIS PHARMACEUTICAL CORP - Form 8-K

MEDICIS PHARMACEUTICAL CORP

Form 8-K

August 19, 2003

=====

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15 (d) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): August 13, 2003

Medicis Pharmaceutical Corporation  
(Exact Name of Registrant as Specified in Charter)

Delaware  
(State or Other Jurisdiction  
of Incorporation)

0-18443  
(Commission File Number)

52-1574808  
(IRS Employer  
Identification No.)

8125 North Hayden Road  
Scottsdale, Arizona  
(Address of Principal  
Executive Offices)

85258-2463  
(Zip Code)

Registrant's telephone number, including area code: (602) 808-8800

N/A

-----  
(Former Name or Former Address, if Changed Since Last Report)

=====

Item 7. Financial Statements and Exhibits

(a) Financial Statements of Business Acquired.

Not Applicable.

(b) Pro Forma Financial Information.

Edgar Filing: MEDICIS PHARMACEUTICAL CORP - Form 8-K

Not Applicable.

(c) Exhibits.

99.1 Copy of press release, dated August 13, 2003, issued by Medicis Pharmaceutical Corporation

Item 9. Regulation FD Disclosure

On August 13, 2003, Medicis Pharmaceutical Corporation issued a press release announcing the expiration and results of the exchange offer for its new 1.5% Contingent Convertible Senior Notes due 2033. A copy of the press release appears as Exhibit 99.1 to this Current Report and is incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

MEDICIS PHARMACEUTICAL CORPORATION (Registrant)

Date: August 18, 2003

/s/ Mark A. Prygocki, Sr. Name: Mark A. Prygocki, Sr. Title: Executive Vice President, Chief Financial Officer, Corporate Secretary and Treasurer

EXHIBIT INDEX

Table with 2 columns: EXHIBIT NUMBER and DESCRIPTION. Row 1: 99.1 Copy of press release, dated August 13, 2003, issued by Medicis Pharmaceutical Corporation.